Green BD - Search Results

1

Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.

Tate M, Chong A, Robinson E, Green BD, Grieve DJ. Tate M, et al. Among authors: green bd. Br J Pharmacol. 2015 Feb;172(3):721-36. doi: 10.1111/bph.12943. Epub 2014 Dec 1. Br J Pharmacol. 2015. PMID: 25231355 Free PMC article. Review.

2

Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.

Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR. Green BD, et al. J Pharmacol Exp Ther. 2006 Aug;318(2):914-21. doi: 10.1124/jpet.105.097824. Epub 2006 Apr 28. J Pharmacol Exp Ther. 2006. PMID: 16648370

3

Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.

Green BD, Flatt PR, Bailey CJ. Green BD, et al. Expert Opin Emerg Drugs. 2006 Sep;11(3):525-39. doi: 10.1517/14728214.11.3.525. Expert Opin Emerg Drugs. 2006. PMID: 16939389 Review.

4

Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

Green BD, Irwin N, Duffy NA, Gault VA, O'harte FP, Flatt PR. Green BD, et al. Eur J Pharmacol. 2006 Oct 10;547(1-3):192-9. doi: 10.1016/j.ejphar.2006.07.043. Epub 2006 Jul 27. Eur J Pharmacol. 2006. PMID: 16945366

5

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

Green BD, Flatt PR, Bailey CJ. Green BD, et al. Diab Vasc Dis Res. 2006 Dec;3(3):159-65. doi: 10.3132/dvdr.2006.024. Diab Vasc Dis Res. 2006. PMID: 17160910 Free article. Review.

6

Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.

Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FP, Flatt PR. Duffy NA, et al. Among authors: green bd. Eur J Pharmacol. 2007 Jul 30;568(1-3):278-86. doi: 10.1016/j.ejphar.2007.05.010. Epub 2007 May 13. Eur J Pharmacol. 2007. PMID: 17573070

7

Incretin hormone mimetics and analogues in diabetes therapeutics.

Green BD, Flatt PR. Green BD, et al. Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):497-516. doi: 10.1016/j.beem.2007.09.003. Best Pract Res Clin Endocrinol Metab. 2007. PMID: 18054732 Review.

8

Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. Green BD, et al. Arch Biochem Biophys. 2008 Oct 15;478(2):136-42. doi: 10.1016/j.abb.2008.08.001. Epub 2008 Aug 7. Arch Biochem Biophys. 2008. PMID: 18708025

9

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Grieve DJ, Cassidy RS, Green BD. Grieve DJ, et al. Among authors: green bd. Br J Pharmacol. 2009 Aug;157(8):1340-51. doi: 10.1111/j.1476-5381.2009.00376.x. Br J Pharmacol. 2009. PMID: 19681866 Free PMC article. Review.

10

Chronic treatment with a stable obestatin analog significantly alters plasma triglyceride levels but fails to influence food intake; fluid intake; body weight; or body composition in rats.

Agnew A, Calderwood D, Chevallier OP, Greer B, Grieve DJ, Green BD. Agnew A, et al. Among authors: green bd. Peptides. 2011 Apr;32(4):755-62. doi: 10.1016/j.peptides.2010.12.005. Epub 2010 Dec 16. Peptides. 2011. PMID: 21167891

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

167 results

Search Page

Filters